Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-N-Glycolyl-GM3 monoclonal antibody - CIMAB

Drug Profile

Anti-N-Glycolyl-GM3 monoclonal antibody - CIMAB

Alternative Names: 14F7; 14F7 humanised mAb; 14F7h; Anti-N-Glycolyl-GM3 antibody 14F7; Humanised monoclonal antibody 14F7; Monoclonal antibody 14F7

Latest Information Update: 28 Jun 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 28 Jun 2018 Clinical development planned for Cancer, including Solid tumours and B-cell lymphoproliferative syndrome (RPCEC00000266; RPCEC00000204)
  • 21 May 2018 Center of Molecular Immunology plans a phase I/II trial for B-cell lymphoproliferative syndrome (Second-line therapy or greater) in Cuba (RPCEC00000266)
  • 08 Sep 2016 The drug is still in preclinical development for Cancer in Cuba (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top